Skip to content
value.today
TrovaGene Inc. logo

TrovaGene Inc.

Formerly Used Kar Parts, Inc., Xenomics, Inc.

Total raised
$10 M
2 rounds on record
Latest round
$4 M
Nov 2012
First round on record
Jun 2009
Today
Went public
See the company page

TrovaGene Inc. is listed today as Cardiff Oncology, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 7 other private sales on record. Open the number of investors for the round's details.

Funding rounds of TrovaGene Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2020$14 MPrivate placement after listing$10 to $50 million

TrovaGene Inc.: Private sale, Jun 2020

Investors in this round

3 investors had bought by the notice of Jun 23, 2020: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark S. Erlander · Executive Officer, Director · Chief Executive Officer
  • Gary Jacob · Director
  • Gary W. Pace · Director
  • James O. Armitage · Director
  • John W. Brancaccio · Director
  • Lale O. White · Director
  • Rodney S. Markin · Director
  • Thomas Adams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Erlander, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 23, 2020. Read the notice at the SEC.

equity, optionsSEC
May 2020$3 MPrivate placement after listing$2 to $10 million

TrovaGene Inc.: Private sale, May 2020

Investors in this round

1 investor had bought by the notice of Jun 1, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark S. Erlander · Executive Officer
  • Gary Jacob · Director
  • Gary W. Pace · Director
  • James O. Armitage · Director
  • John W. Brancaccio · Director
  • Lale O. White · Director
  • Rodney S. Markin · Director
  • Thomas Adams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Erlander, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 1, 2020. Read the notice at the SEC.

equity, optionsSEC
Mar 2020$2 MPrivate placement after listing$2 to $10 million

TrovaGene Inc.: Private sale, Mar 2020

Investors in this round

1 investor had bought by the notice of Apr 14, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas Adams · Executive Officer, Director
  • Gary Jacob · Director
  • Gary W. Pace · Director
  • James O. Armitage · Director
  • John W. Brancaccio · Director
  • Lale O. White · Director
  • Mark S. Erlander · Director
  • Rodney S. Markin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas Adams, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 14, 2020. Read the notice at the SEC.

equity, optionsSEC
Oct 2019$5 MPrivate placement after listing$2 to $10 million

TrovaGene Inc.: Private sale, Oct 2019

Investors in this round

2 investors had bought by the notice of Oct 30, 2019: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,150,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brigitte H. Lindsay · Executive Officer
  • Thomas H. Adams · Executive Officer, Director
  • Athena S. Countouriotis · Director
  • Gary S. Jacob · Director
  • John P. Brancaccio · Director
  • Rodney S. Markin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in IL, NY

Remarks in the notice

  • On fees: “Includes a cash fee of 7.5% of the aggregate gross proceeds raised in the offering including gross proceeds received from the cash exercise of warrants issued in the offering together with other expense reimbursement.”

Signed by Thomas H. Adams, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 30, 2019. Read the notice at the SEC.

equity, optionsSEC
Aug 2019$2 MPrivate placement after listingUnder $2 million

TrovaGene Inc.: Private sale, Aug 2019

Investors in this round

1 investor had bought by the notice of Aug 28, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas Adams · Executive Officer, Director
  • Athena S. Countouriotis · Director
  • Gary Jacob · Director
  • John S. Brancaccio · Director
  • Rodney S. Markin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas Adams, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 28, 2019. Read the notice at the SEC.

equity, optionsSEC
May 2019$2 MPrivate placement after listingUnder $2 million

TrovaGene Inc.: Private sale, May 2019

Investors in this round

1 investor had bought by the notice of May 20, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas Adams · Executive Officer, Director
  • Athena S. Countouriotis · Director
  • Gary Jacob · Director
  • John S. Brancaccio · Director
  • Rodney S. Markin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas Adams, Chief Executive Officer. Source: SEC Form D, newest notice filed May 20, 2019. Read the notice at the SEC.

equity, optionsSEC
Apr 2019$2 MPrivate placement after listingUnder $2 million

TrovaGene Inc.: Private sale, Apr 2019

Investors in this round

1 investor had bought by the notice of Apr 10, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas Adams · Executive Officer, Director
  • Athena S. Countouriotis · Director
  • Gary Jacob · Director
  • John S. Brancaccio · Director
  • Rodney S. Markin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas Adams, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 10, 2019. Read the notice at the SEC.

equity, optionsSEC
Nov 2012$4 MNo. 2$2 to $10 million

TrovaGene Inc.: Raise no. 2, Nov 2012

Investors in this round

8 investors had bought by the notice of Dec 7, 2012: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Antonius Schuh · Executive Officer, Director
  • Steve Zaniboni · Executive Officer
  • Gabriele Cerrone · Director
  • Gary Jacob · Director
  • John Brancaccio · Director
  • Stanley Tennant · Director
  • Thomas Adams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Antonius Schuh, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 7, 2012. Read the notice at the SEC.

equity, optionsSEC
Jun 2009$7 MNo. 1$2 to $10 million

TrovaGene Inc.: Raise no. 1, Jun 2009

Investors in this round

40 investors had bought by the notice of Mar 26, 2012: 40 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Up to $1 million
Sales commissions
$124,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Antonius Schuh · Executive Officer, Director
  • David Robbins · Executive Officer
  • Steve Zanibobi · Executive Officer
  • Gabriele Cerrone · Director
  • Gary Jacob · Director
  • John Brancaccio · Director
  • Stanley Tennant · Director
  • Thomas Adams · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “The above amount represents cash component of sales commissions paid to foreign selling agent. In addition, equity compensation also paid.”
  • On the use of proceeds: “Issuer used proceeds from the offering for working capital purposes which included payment of salaries to named executive officers.”

Signed by /s/ Antonius Schuh, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 26, 2012. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • TrovaGene Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2020).

    SEC Form D · Jun 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2020

That is all the official record says: TrovaGene Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of TrovaGene Inc. are on record.

Investors#

No investor of TrovaGene Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 40 investors.

Largest shareholders today

Institutions holding Cardiff Oncology, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by TrovaGene Inc.
NameRoleNamed in
Mark S. ErlanderChief Executive OfficerJun 2020
Thomas AdamsExecutive officerApr 2020
Brigitte H. LindsayExecutive officerOct 2019
Thomas H. AdamsExecutive officerOct 2019
Antonius SchuhExecutive officerDec 2012
Steve ZaniboniExecutive officerDec 2012
David RobbinsExecutive officerMar 2012
Steve ZanibobiExecutive officerMar 2012
Gary JacobDirectorJun 2020
Gary W. PaceDirectorJun 2020
James O. ArmitageDirectorJun 2020
John W. BrancaccioDirectorJun 2020
Lale O. WhiteDirectorJun 2020
Mark S. ErlanderChief Executive OfficerJun 2020
Rodney S. MarkinDirectorJun 2020
Thomas AdamsDirectorJun 2020
Athena S. CountouriotisDirectorOct 2019
Gary S. JacobDirectorOct 2019
John P. BrancaccioDirectorOct 2019
Thomas H. AdamsDirectorOct 2019
John S. BrancaccioDirectorAug 2019
Antonius SchuhDirectorDec 2012
Gabriele CerroneDirectorDec 2012
John BrancaccioDirectorDec 2012
Stanley TennantDirectorDec 2012

Went public since 2013. Its SEC number is that of a company listed on a stock exchange.